SERODUS ASA RECEIVES APPROVAL OF CLINICAL TRIAL APPLICATION FOR SER150 IN DIABETIC NEPHROPATHY

Oslo, 15 June, 2015: Serodus ASA (Oslo Axess: SER) received approval for a Clinical Trial Application from the German Federal Institute for Drugs and Medical Devices (BfArM) to commence a Phase IIa safety study with SER150 in patients diagnosed with diabetic nephropathy.

“This is yet another important milestone for Serodus. The development of the drug candidate SER150 for diabetic nephropathy is now entering the clinical testing phase in patients. The study will start immediately with opening of the first clinical centers this week.

The study will be running during 2015 and 2016. We expect interim safety results from the first cohort end 2015 and final data second half of 2016.

Diabetic nephropathy is a progressive inflammatory damage of the kidney and is the leading cause of chronic kidney disease in the Western world. Many patients need chronic dialysis when most of the kidney function has been destroyed.  SER150 is expected to diminish the aggressive inflammation significantly and protract loss of renal function and be a valuable drug to treat this increasing number of patients”, said Dr. Eva Steiness CEO of Serodus ASA

 

For more information contact:

Tore Kvam

CFO, Serodus ASA

Mobile: +47 959 34 199

e-mail: tore.kvam@serodus.com

 

Serodus ASA is a Norwegian drug development company, focusing on new therapeutic products for the treatment of cardiovascular and metabolic diseases with large unmet clinical needs. The company's business model is to seek partnering with international pharmaceutical companies after having demonstrated clinical effect in humans. For more information see www.serodus.com.